Cardinal Health makes 2022 predictions for biosimilars in the US

Feb 7, 2022

Cardinal Health published its 2022 Biosimilars Report: The US Journey and Path Ahead.  Cardinal predicted that 2022 is set to be a turning point for biosimilars in the US, reporting that most healthcare providers have a strong interest in using biosimilars to broaden patient access and drive more affordable care for their patients.

Print Page Mail Article